- $680.63m
- $658.47m
Nuvectis Pharma Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Ciprocopan (NXP100) Receives Marketing Approval In China For The Treatment Of Patients With PNH Previously Untreated With Complement Inhibitors
U.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin
U.S. STOCKS ON THE MOVE-Oklo, Fortune Brands, Air Products
Nuvectis Pharma tumbles on deep-discounted $100 mln share sale
Nuvectis Pharma tumbles on planned stock offering
China's Haisco jumps most in 8 months on Nuvectis licensing deal
Nuvectis gains two experimental drugs in licensing deal with China's Haisco (updated)
Nuvectis gains two experimental drugs in licensing deal with China's Haisco
Nuvectis rises as it secures two experimental drugs in licensing deal
Nuvectis Pharma Q1 net loss widens on higher expenses
Brief: Nuvectis Pharma Q1 EPS USD -0.26
Brief: Nuvectis Pharma Announces Upcoming Presentations For Nxp900 At The 2026 American Association
Brief: Nuvectis Pharma, Inc. Reports 2025 Financial Results And Business Highlights
Brief: Nuvectis Pharma Announces The Initiation Of The Phase 1B Study Of NXP900 In Combination With Osimertinib In Patients With NSCLC
Nuvectis Pharma Q3 net loss widens on milestone expenses
Brief: Nuvectis Pharma Q3 EPS USD -0.44
Nuvectis Pharma Q3 net loss widens